Video

Identifying 3 major risk factors for AMD

Author(s):

OT Staff Reports

Joshua Mali, MD, discusses the three major risk factors for developing age-related macular degeneration (AMD).

Joshua Mali, MD, president of the Macular Degeneration Association, vitreoretinal surgeon at The Eye Associates (Sarasota, FL), discusses the three major risk factors for developing age-related macular degeneration (AMD).


See more AMD Awareness content here, here, and here.

Related Videos
Bonnie An Henderson, MD, and EnVision Summit 2025 preview
Adam Wenick, MD, chairs EyeCon session: New treatments in geographic atrophy from detection to intervention
Related Content
4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
December 20th 2024

4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform

EnVision Summit 2025: Advancing Ophthalmology and Optometry Together
November 19th 2024

Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa
December 17th 2024

eyeDNA Therapeutics receives FDA Rare Pediatric Disease Designation for HORA-PDE6b, a novel gene therapy for PDE6b retinitis pigmentosa

EyePod podcast: Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)
November 1st 2024

Innovation Series: Expanding access to eye care, advice for aspiring innovators from DMEI ophthalmology residents (part 3)

EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion
December 16th 2024

EMA CHMP issues positive opinion for aflibercept biosimilar from Celltrion

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis
December 16th 2024

Atsena Therapeutics completes dosing in Part A of phase I/II clinical trial evaluating ATSN-201 to treat X-linked retinoschisis

© 2024 MJH Life Sciences

All rights reserved.